GlassScriptPhysician profile
Shumei Man
NPI 1780947655
$1,030.70
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $333 · 2021: $307 · 2022: $260.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $216.28 | 2019-2022 | |
| Genentech, INC. | $169.63 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $143.01 | 2021-2022 | |
| Abbvie INC. | $124.91 | 2022 | |
| Alexion Pharmaceuticals, INC. | $118.77 | 2021 | |
| Amgen INC. | $114.14 | 2020 | |
| Boston Scientific Corporation | $88.25 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.29 | 2020 | |
| Lilly USA, LLC | $14.37 | 2019 | |
| Portola Pharmaceuticals, LLC | $13.00 | 2020 | |
| Companion Medical, INC. | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shumei Man listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.